The endoplasmic reticulum (ER) is a massive cytoplasmic membrane network that functions primarily to ensure proper folding and posttranslational modification of newly synthesized secreted and transmembrane proteins. Abnormal accumulation of unfolded proteins in this organelle causes a state of "ER stress," which is a hallmark feature of various diseases, including cancer, neurodegeneration, and metabolic dysfunction. Cancer cells exploit the IRE1a-XBP1 arm of the ER stress response to efficiently adjust their protein-folding capacity and ensure survival under hostile tumor microenvironmental conditions. However, we recently found that dendritic cells (DC) residing in the ovarian cancer microenvironment also experience sustained ER stress and demonstrate persistent activation of the IRE1a-XBP1 pathway. This previously unrecognized process disrupts metabolic homeostasis and antigen-presenting capacity in DCs, thereby crippling their natural ability to support the protective functions of infiltrating antitumor T cells. In this review, we briefly discuss some of the mechanisms that fuel ER stress in tumorassociated DCs, the biologic processes altered by aberrant IRE1a-XBP1 signaling in these innate immune cells, and the unique immunotherapeutic potential of targeting this pathway in cancer hosts. Clin Cancer Res; 22(9); 2121-6. Ó2016 AACR.
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Background
Triggering IRE1a-XBP1 activation through the ER stress response
The endoplasmic reticulum (ER) is the primary organelle responsible for regulating intracellular calcium, lipid biosynthesis, and the proper glycosylation and folding of nascent transmembrane and secreted proteins. Numerous physiologic stimuli often found within tumor microenvironments such as nutrient deprivation, calcium store depletion, oxidative stress, hypoxia, and inflammation can disrupt the protein-folding capacity of the ER. When this intrinsic protein folding capacity is overwhelmed, the cell is considered to be in a state of "ER stress" and will initiate an unfolded protein response (UPR) via the ER transmembrane proteins IRE1a (encoded by Ern1), PERK (encoded by Eif2ak3), and ATF6 (encoded by Atf6) in an attempt to restore homeostasis (1) . If the combined action of these three proteins is insufficient to ameliorate ER toxicity, the affected cell will undergo apoptosis.
The serine/threonine-protein kinase/endoribonuclease IRE1a represents the most ancient branch of this signaling pathway, and is highly conserved from yeast to humans. At steady state, the chaperone protein BiP holds IRE1a in its monomeric form, thereby precluding activation. However, upon the induction of ER stress, the accumulating misfolded proteins titrate BiP away from IRE1a, triggering IRE1a dimerization, autophosphorylation, and a conformational shift that licenses its C-terminal endoribonuclease domain to cytoplasmically cleave 26 nucleotides from the Xbp1 mRNA. This spliced transcript is subsequently re-ligated by the tRNA ligase RTCB (2), resulting in a critical reading frame shift that enables translation of the functionally active X-box-binding protein 1 (XBP1). This multitasking transcription factor alleviates ER stress by upregulating a variety of chaperones, redox-dependent foldases, and glycosyltransferases. Beyond these canonical functions, several groups have demonstrated that XBP1 also modulates ER stress-independent, context-specific signaling events such as the hypoxia response (by dimerizing with hypoxiainducible factor-1a; HIF-1a; ref. 3) , lipid metabolism (4), estrogen receptor activity (5) , and the transcription of proinflammatory cytokines (6) .
Biologic functions for IRE1a-XBP1 signaling
Multiple groups have identified key roles for IRE1a-XBP1 signaling in a number of organs and cell types through the use of conditional mouse models. Germline Xbp1 deletion is embryonic lethal due to fetal liver failure (7) . If this is rescued with a liver-specific Xbp1 transgene, the mice die shortly after birth due to insufficient exocrine pancreas function (8) . However, selective deletion of Xbp1 or Ern1 in the liver of adult mice results in marked reduction in serum triglyceride and cholesterol levels (4, 9) . Selective deletion of Xbp1 in pancreatic b cells results in mild hyperglycemia and glucose intolerance (10) . In the hematopoietic system, XBP1 is a key, cell-intrinsic requirement for plasma cell (11) and eosinophil differentiation (12) , and mice with dendritic cell (DC)-specific Xbp1 deletion exhibit reductions in splenic CD8a dendritic cells (13) . Furthermore, XBP1 optimizes TLRdriven proinflammatory cytokine production in macrophages (6) . Conditional deletion of Xbp1 in the intestinal epithelium triggers Paneth cell death and colitic lesions resembling inflammatory bowel disease (14) . However, this pathology is significantly attenuated in conditional Ern1 knockout animals, suggesting that IRE1a hyperactivation, which can occur after selective deletion of Xbp1, may be involved in exacerbating this inflammatory phenotype (15) . Conditional deletion of Xbp1 in the brain is neuroprotective in mouse models of Huntington disease (16) and amyotrophic lateral sclerosis (17) , whereas XBP1-mediated control of hexosamine biosynthesis in cardiomyocytes is cardioprotective in models of ischemic reperfusion (18) . Finally, animals lacking Ern1 in all tissues except the placenta were viable and generally healthy, but displayed modest hyperglycemia and a reduction in serum antibody levels as predicted (19) . The IRE1a-XBP1 signaling pathway therefore has a number of important physiologic functions spanning multiple organ systems.
Cancer cell-intrinsic roles of IRE1a-XBP1 signaling
Malignant cells manage to survive under hostile conditions such as hypoxia and nutrient starvation via sustained activation of the IRE1a-XBP1 branch of the ER stress response (3, 20) . Indeed, XBP1 expression is increased in breast cancer cells resistant to antiestrogen therapy (21) , and high levels of XBP1S transcripts are significantly associated with poor outcomes in endocrine-treated breast tumors (22) . In addition, it was recently demonstrated in vivo that XBP1 drives triple-negative breast cancer (TNBC) progression by cooperating with HIF-1a to support tumor-initiating cell function and metastatic capacity of cancer cells under harsh environmental conditions (3) . Therapeutic silencing of XBP1 in TNBC cells led to suppression of tumor initiation, progression, metastasis, and recurrence, and high expression of XBP1-dependent gene signatures was found to be associated with worse prognosis in TNBC patients (3) . XBP1 has also been demonstrated to drive the pathogenesis of multiple myeloma (23) , and has been implicated in cancer cell dedifferentiation, susceptibility to oncovirus infection, and the epithelial-to-mesenchymal transition (24) . Seminal work by Tang and colleagues (25) also demonstrated constitutive IRE1a-XBP1 activation in murine chronic lymphocytic leukemia (CLL) cells, which promoted their pathogenesis in vivo. Accordingly, targeting IRE1a signaling in vivo with the selective small-molecule endoribonuclease inhibitor B-I09 showed significant therapeutic effects, especially when used in combination with targeted antileukemic agents such as ibrutinib. In a xenograft model of human glioma, inhibiting IRE1a function by overexpressing a dominant-negative variant significantly increased overall survival by decreasing tumor growth rate and angiogenesis (26) . Furthermore, recent in vivo studies have also indicated that IRE1a-XBP1 signaling supports the aggressiveness of pancreatic cancer cells, and abrogating IRE1a activity using the-small molecule inhibitor STF-083010 induced apoptosis and consequently delayed pancreatic tumor growth in xenograft models (27) . Increasing evidence hence demonstrates that sustained IRE1a-XBP1 activation operates directly in cancer cells to promote tumor growth and metastasis in vivo in a variety of aggressive cancer types, many of which currently lack targeted therapies.
Immune cell dysfunction driven by abnormal IRE1a-XBP1 signaling
Although IRE1a-XBP1 signaling has been shown to positively influence the growth and survival of malignant cells, the role of this cellular pathway in shaping the cancer immunoenvironment and the antitumor immune response had not been explored. Aggressive cancers recruit a broad collection of immune cells and effectively manipulate their intrinsic protective activity as a fundamental protumoral mechanism. This process is epitomized by ovarian carcinoma, a highly immunosuppressive and lethal cancer that exquisitely controls normal DC functions to abrogate the generation of protective T-cell-based responses (28) . We hypothesized that common adverse conditions in the ovarian cancer microenvironment that induce protein misfolding (e.g., hypoxia, nutrient deprivation, and/or oxidative stress) could trigger ER stress and robust activation of the IRE1a-XBP1 pathway in tumorassociated DCs (tDC), a process that might influence their normal activity. Unlike DCs in nontumor sites, DCs residing in human and mouse ovarian cancers exhibited robust and sustained IRE1a-XBP1 activation and concomitant overexpression of XBP1-dependent genes involved in the ER stress response (13) . Mechanistically, high levels of reactive oxygen species (ROS) in tDCs promoted intracellular lipid peroxidation and subsequent generation of reactive byproducts such as 4-hydroxynonenal (4-HNE), which induced ER stress by directly modifying critical ER-resident proteins and chaperones (ref. 13 ; Fig. 1 ). Treatment with antioxidants or pharmacologic agents that efficiently sequester lipid peroxidation byproducts therefore prevented the induction of ER stress and IRE1a-XBP1 activation in DCs exposed to tumor-derived factors like those commonly present in malignant ovarian cancer ascites (13) . We are currently defining the molecular mechanisms by which the tumor microenvironment fuels ROS accumulation and lipid peroxidation in tDC. Interestingly, lipid peroxidation byproducts have also been shown to promote vascular inflammation and atherogenesis by triggering ER stress in endothelial cells (29) . Most importantly, ovarian cancer-bearing mice selectively lacking Xbp1 in DCs showed delayed progression of primary and metastatic ovarian tumors in three distinct preclinical models of disease (13) . These effects correlated with enhanced intratumoral infiltration of activated, antigen-experienced T cells producing IFNg in situ (13), suggesting that tDCs devoid of Xbp1 were immunocompetent, rather than immunosuppressive. Global transcriptional profiling of tDCs revealed that constitutively active XBP1 not only promoted the expression of canonical XBP1-target genes involved in the ER stress response, but also induced a robust triglyceride biosynthetic program leading to abnormal lipid accumulation ( Fig. 1; ref. 13 ). Interestingly, XBP1 had previously been demonstrated to drive hepatic lipogenesis by inducing the expression of key lipid biosynthetic genes (4) . Seminal studies by the group of Herber and colleagues (30) had also uncovered that a major mechanism contributing to DC malfunction in cancer is indeed abnormal intracellular lipid accumulation. This dyslipidemia was shown to inhibit the efficient loading of antigenic peptides onto MHC-I molecules, thereby impairing optimal antigen cross-presentation to T cells by DCs. Consistent with this concept, Xbp1-deficient tDCs unable to accumulate intracellular lipid droplets showed enhanced capacity to support T-cell function both in vitro and in vivo, and memory (tumor-reactive) T cells generated in ovarian cancer-bearing mice selectively lacking Xbp1 in DCs showed enhanced antitumor capacity when adoptively transferred into wild-type ovarian cancer hosts (13) . We are currently exploring additional (lipid metabolism-independent) mechanisms by which sustained IRE1a-XBP1 activation promotes DC dysfunction in the tumor microenvironment.
Depleting or "licensing" tumor-associated myeloid cells in vivo has been widely used to restrain the optimal progression of several cancer types, but the precise microenvironmental conditions and molecular pathways that tumors exploit in these immune cells to co-opt their otherwise protective activity remain poorly understood. Our study provides the first evidence of a lethal cancer capable of co-opting IRE1a-XBP1 function in DCs of the tumor microenvironment as a strategy to evade immune control. This process may also orchestrate tolerance and immunosuppression in other lethal solid tumors that commonly rely on infiltrating innate immune cells to promote malignant progression. Future studies therefore aim at defining whether other cell types in the ovarian cancer immunoenvironment exhibit detrimental ER stress responses, and whether additional tumor types also rely on IRE1a-XBP1 signaling as a major immunosuppressive mechanism.
Clinical-Translational Advances

Small-molecule inhibitors
Given that IRE1a-XBP1 signaling sustains both cancer cellextrinsic immunosuppression and cancer cell-intrinsic growth and metastasis, there is significant interest in developing targeted therapies against this UPR pathway. Although technical limitations preclude the development of direct small-molecule XBP1 inhibitors, the formation of the active, spliced XBP1 variant can be readily targeted via its dependency on IRE1a. The dual enzyme IRE1a is amenable to small-molecule targeting, and multiple inhibitors have been identified from various independent small-molecule screens (Fig. 2) . Several crystal structures of IRE1a in complex with either kinase inhibitors or hydroxyl-aryl-aldehyde endoribonuclease inhibitors have been reported (31, 32) , enabling rational development of novel IRE1a inhibitors.
Small-molecule IRE1a inhibitors can be grouped into three main categories based on their structures and mode of action. The first group consists of inhibitors with indirect or unknown mechanisms of action, and includes irestatin, trierixin (33) , and quinotrierixin (34) . These compounds were each identified by screening small-molecule libraries against human cell lines expressing IRE1a endoribonuclease-driven luciferase reporter plasmids in the presence of chemical ER stressors such as thapsigargin or tunicamycin. In these reporter systems, the firefly luciferase cDNA is fused out of frame to a fragment of human XBP1 cDNA bearing IRE1a splicing recognition sites, and is only translated in-frame upon IRE1a-mediated RNA splicing. The IRE1a inhibitory capacity for each inhibitor was subsequently confirmed with luciferase-independent, PCR-based methods in human cell lines. However, the mechanisms underlying inhibitor activity remain poorly defined, and it is unclear whether these compounds specifically target IRE1a or whether they interfere with UPR activation more generally, as has been suggested for quinotrierixin (34) .
The second and largest group of inhibitors is composed of direct IRE1a endoribonuclease inhibitors. Some of these compounds were identified in high-throughput screens against the endoribonuclease activity of the purified IRE1a cytoplasmic domain, while others were developed during optimization efforts on preexisting leads. Most of these compounds, including 3-ethoxy-5,6-dibromosalicylaldehyde (35) derivatives, which generally share a core hydroxyl-aryl-aldehyde (HAA) structure. Crystallographic analyses have demonstrated that these HAA inhibitors bind covalently to lysine K907, which resides in a shallow, solvent-exposed pocket on the IRE1a endoribonuclease domain (31) . However, this HAA motif is not an absolute structural requirement, as both STF-083010 (38) the nucleoside-type antibiotic analogue toyocamycin can also directly block the IRE1a endoribonuclease (39) . All direct IRE1a endonuclease inhibitors dose dependently reduced XBP1 splicing in vitro in human cell lines without affecting IRE1a phosphorylation or signaling from PERK and ATF6. Importantly, STF-083010 (38), MKC-3946 (37), and toyocamycin (39) demonstrated efficacy against multiple myeloma both in vitro and in xenograft survival studies, and B-I09 reduced tumor burden in a genetic mouse model of CLL driven by the Em-TCL1 transgene (25) . Furthermore, daily intraperitoneal administration of 4m8C significantly reduced pathologic joint swelling in the KBxN serum transfer murine model of rheumatoid arthritis (40) . Cumulatively, these reports validate IRE1a as an attractive clinical target and indicate that the endoribonuclease domain is chemically tractable.
The final group of small-molecule IRE1a inhibitors is kinase inhibitors, which act allosterically to disrupt endoribonuclease function. Compared with the extensive and rapidly expanding collection of endoribonuclease inhibitors, IRE1a kinase inhibitors are considerably less well developed despite their significant therapeutic potential. This disparity may be due to, in part, to nuances in how the IRE1a endoribonuclease domain responds to different classes of kinase inhibitors. When the IRE1a kinase DFG loop shifts into a "DFG-in" conformation, a structure stabilized by certain type I kinase inhibitors, such as sunitinib and a novel compound known as "Compound 3," the endoribonuclease domain cleaves the Xbp1 mRNA in the absence of IRE1a autophosphorylation (41) . However, upon adopting a "DFG-out" conformation, which can be enforced with certain type II kinase inhibitors such as KIRA6 and AD60 (42) , both the kinase domain and the endoribonuclease domain are rendered inert (43) . Interestingly, in male Ins2 þ/Akita mice, which express a mutated pro-insulin that causes chronic ER stress in pancreatic b cells, twice-daily administration of KIRA6 reduced plasma glucose levels and improved glucose tolerance test outcomes (43) . Furthermore, intravitreal KIRA6 injection in the P23H rhodopsin transgenic rat model of retinitis pigmentosa preserved photoreceptor viability and function (43) . These in vivo data are consistent with accumulating evidence suggesting that protein misfolding and ER stress may be linked to both metabolic dysfunction and retinal degeneration. Though kinase domains are highly structurally conserved, extremely selective IRE1a kinase inhibitors can be Potential therapeutic strategies for targeting IRE1a-XBP1 signaling in cancer-associated DCs. The IRE1a kinase and endoribonuclease domains can be individually blocked with small molecules. In addition, the constitutive activation of either XBP1 or IRE1a can be reduced using nanoparticles encapsulating siRNAs. In terms of DC-based vaccines or autologous DC transfer, IRE1a or XBP1 could be selectively ablated ex vivo through the use of virally delivered DNA editing technologies such as zinc finger nucleases, TALENs, and CRISPR/CAS9. Genome-edited DCs could then be transplanted back into patients to enhance standard therapeutic regimens. generated, as illustrated by the recently reported "Compound 18" and GSK2850163 (32, 44) . However, the in vivo effects of these selective compounds were not reported. Type II kinase inhibition, but not type I kinase inhibition, therefore represents a second pharmacologically tractable strategy for globally blocking IRE1a endoribonuclease activity in the tumor microenvironment.
Immune cell-specific approaches
Because of the unique properties of the immune system, other small-molecule independent strategies could also be utilized to disable IRE1a-XBP1 signaling selectively in DCs of cancer hosts. First, DCs within malignant ovarian cancer ascites have exceptional phagocytic capacity, rendering them excellent targets for nanoparticle-mediated RNAi therapeutics (45) . As ovarian cancer metastasis is generally confined within the peritoneal cavity, intraperitoneal administration of siRNA-loaded nanoparticles targeting ERN1 or XBP1 represents a novel and feasible immuno-oncology strategy. In animal models of established metastatic ovarian cancer, silencing Xbp1 expression using this approach rendered tDCs highly immunostimulatory and significantly extended host survival by stimulating T-cell-mediated antitumor immunity (13) .
As a second strategy, the genes encoding IRE1a or XBP1 could be ablated to enhance the efficacy of autologous DC adoptive transfer strategies. Despite the modest successes of adoptive DC therapy, ovarian cancer patients were resistant to similar tumor antigen-pulsed adoptive DC treatments (46) . Genome-editing technologies such as CRISPR/CAS9, zinc finger nucleases, or TALENs (47) should enable precise and efficient mutation of XBP1 or ERN1 in DCs before adoptive transfer, thereby protecting these transplanted DCs from the suppressive effects of aberrant ER stress responses induced by the tumor microenvironment. In proof-of-concept experiments, we demonstrated that transferring Xbp1-deficient bone marrow-derived cells (BMDC) into mice with established primary ovarian cancer significantly delayed tumor progression compared with infusion of wild-type BMDCs (13) . Strikingly, transplanted Xbp1-deficient DCs were dominantly immunostimulatory over the endogenous (wildtype) regulatory DCs residing in the tumor microenvironment. Hence, cutting-edge genetic methods for targeting IRE1a-XBP1 signaling would likely enhance the efficacy of current adoptive DC therapies in ovarian cancer.
To conclude, the IRE1a-XBP1 branch of the ER stress response is a novel and well-characterized pathway with significant therapeutic relevance in a variety of human cancers. This molecular pathway controls unique biologic processes in the cancer cell and in tumor-infiltrating immune cells to ultimately promote tumor progression. Although IRE1a-XBP1 signaling can be targeted through a variety of classical and nonclassical methods (Fig. 2) , potent small-molecule inhibitors represent an attractive strategy to simultaneously disable this protumoral pathway in the cancer cell and in the innate immune system.
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